Statin treatment following coronary artery stenting and one-year survival.

[1]  Deepak L. Bhatt,et al.  Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention , 2002, Circulation.

[2]  S. Fichtlscherer,et al.  Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. , 2001, Journal of the American College of Cardiology.

[3]  M. Ezekowitz,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.

[4]  F Unger,et al.  Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. , 2001, The New England journal of medicine.

[5]  R. Califf,et al.  Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study , 2001, The Lancet.

[6]  A. Zeiher,et al.  Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the Pl(A2)allele of the platelet glycoprotein IIIa gene. , 2001, European heart journal.

[7]  D. Wood,et al.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.

[8]  L. Wallentin,et al.  Early statin treatment following acute myocardial infarction and 1-year survival. , 2001, JAMA.

[9]  D W Bates,et al.  Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. , 2001, Archives of internal medicine.

[10]  U. Laufs,et al.  Suppression of Endothelial Nitric Oxide Production After Withdrawal of Statin Treatment Is Mediated by Negative Feedback Regulation of Rho GTPase Gene Transcription , 2000, Circulation.

[11]  W. Palinski Immunomodulation: a new role for statins? , 2000, Nature Medicine.

[12]  A. Zeiher,et al.  Effect of statin therapy on restenosis after coronary stent implantation. , 2000, The American journal of cardiology.

[13]  M. Linton,et al.  Current perspectives on statins. , 2000, Circulation.

[14]  P. Rosenbaum,et al.  Invited commentary: propensity scores. , 1999, American journal of epidemiology.

[15]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[16]  T. Investigators Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[17]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[18]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[19]  H. Krumholz,et al.  When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. , 1997, Circulation.

[20]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[21]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[22]  Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[23]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[24]  W. O’Neill,et al.  Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. , 1994, The New England journal of medicine.

[25]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[26]  E J Topol,et al.  Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.

[27]  P. Serruys,et al.  A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. , 1999, European heart journal.

[28]  D Blumenthal,et al.  Variations in cholesterol management practices of U.S. physicians. , 1997, Journal of the American College of Cardiology.

[29]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[30]  K. Anderson,et al.  An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.

[31]  N E Day,et al.  Statistical methods in cancer research. IARC Workshop 25-27 May 1983. , 1987, IARC scientific publications.